Oncogenic IL7RA mutations were described by our group and others [61,62,63,64,65,66] in approximately 9% of T-ALL cases [61], 7.8% of early T phenotype ALL (ETP-ALL) cases [67], 2%–3% of B-ALL cases [62,68] and 12% of Ph-like B-ALL subtype [68,69,70]. This evidence concerns the gene IL7R and acute lymphoblastic leukemia.